BBNX

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Wall Street analysts forecast BBNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBNX is 30.57 USD with a low forecast of 23.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Beta Bionics Inc revenue for the last quarter amounts to 27.25M USD, increased 63.14 % YoY.

Beta Bionics Inc. EPS for the last quarter amounts to -0.33 USD, increased 43.48 % YoY.

Beta Bionics Inc (BBNX) has 291 emplpoyees as of January 11 2026.

Today BBNX has the market capitalization of 886.66M USD.